← 返回

同时性女性双侧乳腺癌的演化与治疗反应

英文原题:Evolution of synchronous female bilateral breast cancers and response to treatment.

查看英文原题

Evolution of synchronous female bilateral breast cancers and response to treatment.

PubMed 2023/03/06(内容时间) Nat Med Q1 · IF 52.5(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

同步双侧乳腺癌(sBBC)发生于双侧乳房受到相同胚系遗传因素和环境暴露影响之后。关于sBBC免疫浸润及治疗应答的证据很少。本文显示,乳腺癌亚型对TIL(肿瘤浸润淋巴细胞)(TIL,n=277)水平和病理完全缓解(pCR,n=140)率的影响,取决于对侧肿瘤亚型与本侧肿瘤亚型是否一致:与对侧肿瘤亚型一致的管腔型乳腺癌相比,对侧肿瘤亚型不一致者TIL水平更高、pCR率也更高。肿瘤测序显示,左、右侧肿瘤(n=20)在体细胞突变、拷贝数改变和克隆系统发育方面彼此独立;而原发肿瘤与残留病灶无论从体细胞突变还是转录组角度均密切相关。本研究提示,肿瘤内在特征可能影响肿瘤免疫与pCR之间的关联,并显示对侧肿瘤特征也与免疫浸润和治疗应答相关。

展开英文摘要原文

Synchronous bilateral breast cancer (sBBC) occurs after both breasts have been affected by the same germline genetics and environmental exposures. Little evidence exists regarding immune infiltration and response to treatment in sBBCs.

Here we show that the impact of the subtype of breast cancer on levels of tumor infiltrating lymphocytes (TILs, n = 277) and on pathologic complete response (pCR) rates (n = 140) differed according to the concordant or discordant subtype of breast cancer of the contralateral tumor: luminal breast tumors with a discordant contralateral tumor had higher TIL levels and higher pCR rates than those with a concordant contralateral tumor.

Tumor sequencing revealed that left and right tumors (n = 20) were independent regarding somatic mutations, copy number alterations and clonal phylogeny, whereas primary tumor and residual disease were closely related both from the somatic mutation and from the transcriptomic point of view.

Our study indicates that tumor-intrinsic characteristics may have a role in the association of tumor immunity and pCR and demonstrates that the characteristics of the contralateral tumor are also associated with immune infiltration and response to treatment.

论文信息

作者
Hamy AS、Abécassis J、Driouch K、Darrigues L、Vandenbogaert M、Laurent C、Zaccarini F、Sadacca B
第一作者单位
Department of Medical Oncology, Institut Curie, Université Paris Cité, Paris, France.France
通讯作者单位
Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, Paris, INSERM, U932 Immunity and Cancer, Institut Curie, Université de Paris, Paris, France. fabien.reyal@curie.fr.France
文献类型
非美国政府资助研究
期刊
Nature medicine2023 Mar
原文标识
PubMed 36879128 · DOI 10.1038/s41591-023-02216-8